Published in Arterioscler Thromb Vasc Biol on January 20, 2005
The in vitro real-time oscillation monitoring system identifies potential entrainment factors for circadian clocks. BMC Mol Biol (2006) 0.97
The Role of miR-378a in Metabolism, Angiogenesis, and Muscle Biology. Int J Endocrinol (2015) 0.82
Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid. J Lipid Res (2013) 0.78
15-deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases. J Inflamm (Lond) (2008) 0.77
Protective Actions of PPAR-gamma Activation in Renal Endothelium. PPAR Res (2009) 0.75
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A (2005) 1.84
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med (2010) 1.54
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem (2003) 1.43
Genomic structures of the human and murine corin genes and functional GATA elements in their promoters. J Biol Chem (2002) 1.37
Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem (2003) 1.27
Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem (2003) 1.22
Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem (2002) 1.21
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum (2009) 1.07
Rev-erbalpha upregulates NF-kappaB-responsive genes in vascular smooth muscle cells. FEBS Lett (2004) 1.03
Efficacy of a novel class of RNA interference therapeutic agents. PLoS One (2012) 0.99
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery (2010) 0.97
A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract (2009) 0.97
Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem (2011) 0.91
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res (2004) 0.90
RORalpha1 and RORalpha4 suppress TNF-alpha-induced VCAM-1 and ICAM-1 expression in human endothelial cells. FEBS Lett (2004) 0.88
Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology (2012) 0.88
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem (2012) 0.88
Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol (2011) 0.87
Microfluidic impedance cytometer for platelet analysis. Lab Chip (2013) 0.87
Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem (2011) 0.86
A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost (2007) 0.85
Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol (2010) 0.85
Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol (2005) 0.84
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. J Neurotrauma (2004) 0.84
Atherosclerosis amelioration by moderate alcohol consumption is associated with increased circulating levels of stromal cell-derived factor-1. Circ J (2011) 0.83
Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. Am J Respir Cell Mol Biol (2013) 0.83
Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med (2010) 0.83
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol (2006) 0.81
A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost (2007) 0.81
Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol (2008) 0.80
Lipopolysaccharide attenuates thrombolysis in batroxobin-induced lung vasculature fibrin deposition but not in ferrous chloride-induced carotid artery thrombus in rats: role of endogenous PAI-1. Thromb Res (2003) 0.80
3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett (2006) 0.80
Differential gene expression in thrombomodulin (TM; CD141)(+) and TM(-) dendritic cell subsets. PLoS One (2013) 0.80
Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem (2007) 0.79
Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem (2002) 0.79
The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem (2008) 0.79
Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res (2008) 0.79
Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost (2003) 0.78
Structures of potent selective peptide mimetics bound to carboxypeptidase B. Acta Crystallogr D Biol Crystallogr (2008) 0.78
Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma. Lung (2011) 0.78
Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thromb Res (2008) 0.78
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb Haemost (2008) 0.78
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front Biosci (2002) 0.77
The coagulation and protein C pathways in patients with sleep apnea. Lung (2009) 0.77
P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1. Thromb Haemost (2004) 0.77
Different bile concentration of micafungin and itraconazole in a patient with candidal cholecystitis. J Infect (2009) 0.77
Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease. Helicobacter (2009) 0.76
A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost (2007) 0.76
Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. J Biol Chem (2003) 0.75
Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa. Biochem Pharmacol (2003) 0.75
Erratum. Amelioration of Diabetes by Protein S. Diabetes 2016;65:1940-1951. Diabetes (2016) 0.75
Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction. Pharmacology (2005) 0.75